News

Tired of Securities Enforcement Actions Targeting the Life Sciences Industry?

Wednesday, June 19, 2019

12:00–1:00pm ET
Arnold & Porter Webinar

The SEC and DOJ continue to prioritize investigations of life sciences companies specific to disclosures regarding FDA communications and internal control issues, the Foreign Corrupt Practices Act (FCPA), and insider trading and general fraud.

Please join a team of Arnold & Porter attorneys and former government prosecutors for an update on recent enforcement actions and trends, lessons learned, and a discussion of how to identify and mitigate key compliance risks for life sciences companies.

Webinar Series Information

Counsel and compliance professionals at life sciences companies must be prepared to identify, assess and mitigate the potential risks to their businesses stemming from surging whistleblower activity and aggressive governmental investigations and private securities litigation.

Securities Enforcement and Disputes in the Life Sciences Industry is a five-part webinar series led by a team of Arnold & Porter attorneys comprised of former SEC, DOJ, and other seasoned litigators with decades of experience handling life sciences-related securities enforcement and disputes. The series is designed for life sciences company counsel and compliance professionals at all levels, equipping attendees with the tools needed to manage critical issues that arise in securities enforcement and litigation. Each webinar is self-contained and stands alone; those interested can attend one, some, or all sessions as they like. Detailed information on previous and forthcoming webinars is linked below.

Thursday, May 30, 2019
» Securities Litigation Exposure for Life Science Companies

Wednesday, September 18, 2019
» The Perfect Storm: Handling Concurrent Governmental Investigations, Internal Investigations and Private Securities Litigation

Wednesday, October 16, 2019
» M&A Litigation and Commercial Disputes

Wednesday, November 13, 2019
» Ethics Considerations When Interacting With Current and Former Employees During Investigations and Litigation

Email Disclaimer